NCT07037004View on ClinicalTrials.gov

Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

May 4, 2026

Primary Completion Date

May 4, 2027

Study Completion Date

May 4, 2027

Conditions
Clear Cell Renal Cell CarcinomaSarcomatoid Renal Cell CarcinomaStage II Renal Cell Cancer AJCC v8Stage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

DRUG

Clostridium butyricum CBM588 Strain

Given PO

PROCEDURE

Computed Tomography

Undergo CT

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (2)

91010

City of Hope Medical Center, Duarte

92618

City of Hope at Irvine Lennar, Irvine

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER